Human epidermal growth factor receptor 2 testing recommendation.
作者信息
Raji Adekunle, Lurie Robert H
出版信息
Arch Pathol Lab Med. 2007 Sep;131(9):1330-1; author reply 1331-3. doi: 10.5858/2007-131-1330b-HEGFRT.
Abstract
摘要
相似文献
1
Human epidermal growth factor receptor 2 testing recommendation.
Arch Pathol Lab Med. 2007 Sep;131(9):1330-1; author reply 1331-3. doi: 10.5858/2007-131-1330b-HEGFRT.
2
Counterpoint: Both immunohistochemistry and fluorescence in situ hybridization play important roles for HER2 evaluation.
Clin Chem. 2011 Jul;57(7):983-5. doi: 10.1373/clinchem.2010.160853. Epub 2011 May 10.
3
Human epidermal growth factor receptor 2 testing: where are we?
J Clin Oncol. 2010 Oct 1;28(28):4289-92. doi: 10.1200/JCO.2010.29.5071. Epub 2010 Aug 9.
4
Experts debate value of HER2 testing methods.
J Natl Cancer Inst. 2000 Feb 16;92(4):292-4. doi: 10.1093/jnci/92.4.292.
5
[HER2 testing in breast cancer].
Nihon Rinsho. 2007 Jun 28;65 Suppl 6:275-80.
6
Accuracy and precision in HER2/neu testing in breast cancer: are we there yet?
Hum Pathol. 2004 Feb;35(2):143-6. doi: 10.1016/j.humpath.2004.01.002.
7
HER2--a discussion of testing approaches in the USA.
Ann Oncol. 2001;12 Suppl 1:S101-7. doi: 10.1093/annonc/12.suppl_1.s101.
8
Human epidermal growth factor receptor 2 testing in 2010: does chromosome 17 centromere copy number make any difference?
J Clin Oncol. 2010 Oct 1;28(28):4293-5. doi: 10.1200/JCO.2010.29.6673. Epub 2010 Aug 9.
9
HER2 status in breast cancer--an example of pharmacogenetic testing.
J R Soc Med. 2007 Jul;100(7):326-9. doi: 10.1177/014107680710000715.
10
HER-2 and fluorescent in situ hybridization to evaluate breast cancer.
JAMA. 2004 Jul 21;292(3):328; author reply 328-9. doi: 10.1001/jama.292.3.328-a.
Zotero 插件